ReviewPathologica2022
News in the classification of WHO 2022 bladder tumors.
Review in Pathologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 26 citations in OpenAlex.
- Serial H&E Pathology Reveals Progression-Associated Nuclear Size Drift as a Longitudinal Digital Readout of Bladder Cancer Evolution.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The Association Between Neutrophil-to-Lymphocyte Ratio and Histological Tumor Differentiation in Solid Malignancies: A Systematic Review.Diagnostics (Basel, Switzerland) · 2026Review
- Multi-DECT image-based intra- and peritumoral interpretable radiomics and artificial intelligence models for preoperative prediction of pathological grading of non-muscle-invasive bladder cancer.Abdominal radiology (New York) · 2026Article
- Histological Subtypes of Bladder Cancer: Epidemiology, Molecular Biology, and Clinical Implications.Cancers · 2026Review
- Low grade T1 non-muscle invasive urothelial carcinoma in pediatric patient: A rare case report and management dilemma.Urology case reports · 2026Article
- Bladder sarcomatoid carcinoma and giant cell carcinoma without recurrence after robot-assisted radical cystectomy: A case report.Urology case reports · 2026Article
- Neoplasms arising at the CIED pocket: a hybrid study combining a case report, scoping review, and clinical survey.Internal and emergency medicine · 2026Article
- Divergent Differentiation and Histologic Subtypes in Upper Tract Urothelial Carcinoma Demonstrate Distinct Patterns of Extraurothelial Recurrence.European urology open science · 2026Article
- [Treatment options in rare urological tumors: potential of molecular tumor boards].Urologie (Heidelberg, Germany) · 2026Review
- CD36 rs1761667 Polymorphism and Its Impact on Molecular Signatures in Bladder Cancer.Diseases (Basel, Switzerland) · 2026Article
- Identification and experimental validation of prognostic genes associated with dietary restriction-related signatures in bladder cancer.Frontiers in immunology · 2026Article
- Trends in the diagnosis of variant bladder cancer: a national retrospective cohort analysis.Frontiers in oncology · 2026Article
- Genomic Characteristics of Bladder Cancer: An AACR Project GENIE Study.International journal of molecular sciences · 2025Article
- Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies.Nature reviews. Urology · 2025Review
- CENPF overexpression in bladder cancer cells enhances proliferation, migration, invasion, and apoptosis.Scientific reports · 2025Article
- Optimizing enfortumab vedotin plus pembrolizumab therapy.Oncotarget · 2025Review
- Frequency and Characterization of Rare Histologic Subtypes in Canine Invasive Urothelial Carcinoma.bioRxiv : the preprint server for biology · 2025Article
- Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes.American journal of clinical pathology · 2025Article
- Is miR-10a a tumor suppressor that modulates proliferation and invasion in high-grade bladder cancer?Oncology research · 2025Article
- Modeling and validation of serum miR-18a and miR-122 levels as predictors of recurrence after laparoscopic radical cystectomy procedure for bladder cancer based on nomogram model.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The fifth-edition of World Health Organization (WHO) Classification of Tumors series for urinary and male genital tract tumors has been published, six years later the fourth-edition. In these years, new treatment approaches have been implemented and new molecular data on urological cancers are known. Morphology remains the groundwork for taxonomy of the urinary tract tumors. However, a molecular approach to classification of urothelial carcinomas and the management of selected neoplasms with new therapeutic modalities such as immunotherapy are emerging. More data are needed for the application of these advances in routine pathology practice and patient management. The 2022 World Health Organization (WHO) Classification of Tumors of the Urinary System and Male Genital Organs represents an update in classification on urinary tract tumors. It also offers new insights with regards to the grading of heterogeneous non-invasive urothelial neoplasms, the definition of inverted neoplasms, the grading of invasive urothelial carcinomas, the diversity of morphological appearance of urothelial carcinomas, the definition of precursor lesions and the lineage of differentiation of the tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.